Research agreement with Stanford University

Hofseth BioCare has signed a two-year research agreement with Stanford University School of Medicine, CA, USA to further investigate the gastro-intestinal (GI)-protective properties of HBC’s Salmon Protein Hydrolysate Peptides (“SPH”) in children and adults with GI tract disorders.
Pro Go 1200x490

Hofseth BioCare has signed a two-year research agreement with Stanford University School of Medicine, CA, USA to further investigate the gastro-intestinal (GI)-protective properties of HBC’s Salmon Protein Hydrolysate Peptides (“SPH”) in children and adults with GI tract disorders.

The research agreement follows recent findings of SPH’s reduction of GI injury in both in vitro and in vivo pre-clinical models that reflect the underlying disease process of necrotizing enterocolitis (NEC) and ulcerative colitis / inflammatory bowel disease (IBD).

The focus of the research collaboration is to further elucidate how SPH reduces or prevents intestinal inflammation in preclinical models of NEC and IBD and thereby helps to restore GI barrier function. In the second year of the project, it is anticipated that this work may form the basis for proceeding to a pilot study to assess SPH as an adjunctive treatment for the maintenance of remission in human subjects with mild to moderate ulcerative colitis.

Prior research undertaken by HBC and Stanford has demonstrated that gene systems that protect the GI tract against oxidative stress and inflammation are upregulated in human GI cells exposed to SPH. In proprietary animal models of GI inflammation, Stanford’s work has shown SPH to markedly reduce gut inflammation. Oxidative stress is implicated as an important underlying driver of many digestive diseases, including NEC and IBD.


Read more about our Gastrointestinal (GI) Research Program